An update to Quantib Prostate 2.1, Quantib Prostate 3.0 reportedly facilitates workflow advances and offers a variety of tools, ranging from artificial intelligence (AI)-based segmentation to PI-RADS scoring support, to help improve interpretation of prostate magnetic resonance imaging (MRI).
The Food and Drug Administration (FDA) has granted 510(k) clearance to Quantib Prostate 3.0 (RadNet), an artificial intelligence (AI)-based software that may bolster radiology workflow and interpretation of prostate magnetic resonance imaging (MRI).
Key features for Quantib Prostate 3.0, an update to Quantib Prostate 2.1 software, include an improved algorithm for prostate and subregion segmentation and automated lesion drawing on the PI-RADS sector map, according to RadNet.
The company adds that other benefits for enhancing the quality and speed of prostate MRI reporting include PSA (prostate-specific antigen) density calculation, one-click segmentation of lesion candidates, and precise registration and movement correction.
“The (clearance) of Quantib Prostate 3.0 represents another step forward in advancing prostate cancer care by bringing the latest in AI technology to MRI interpretation,” noted Gregory Sorenson, M.D., the president of RadNet’s AI Division. “With the increasing recognition of the important role MRI plays in prostate cancer diagnosis, we believe physicians will value the power that this software puts in their hands.”
(Editor’s note: For related content, see “Emerging Prostate and Brain MRI AI Platform Gets FDA Nod” and “Can Explainable AI Enhance Diagnosis and PI-RADS Classification of Prostate Cancer on MRI?”)
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Study: PSMA PET/CT More Advantageous than MRI for Locoregional Staging of Prostate Cancer
July 8th 2024For men with prostate cancer, new research demonstrates that 18F-PSMA-1007 PET/CT is 17 percent more accurate than mpMRI at identifying the final pathological tumor stage and 12 percent more accurate in detecting extracapsular extension.
Could MRI-Based AI Offer Better Risk Stratification for Prostate Cancer than PI-RADS?
July 3rd 2024The combination of deep learning assessment of prostate MRI with PI-RADS classification at a 15 percent risk threshold spared 49 percent of biopsies in comparison to 37 percent employing a PI-RADS>4 only cut-ff approach, according to new research.